LEXINGTON, Mass., Sept. 4, 2018 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of
immune checkpoint antibodies, cancer vaccines and adoptive cell
therapies1, announced today that Jennifer Buell, Ph.D., Chief Communications and
External Affairs Officer at Agenus and Robert Stein, MD, PhD, Senior R&D Advisor at
Agenus, will make a presentations and host one-on-one meetings with
investors at the 2018 Annual B. Riley FBR Healthcare Conference, at
NY Marriott East Side in New York
City.
Details of the presentation are provided below:
- Presenter: Jennifer S. Buell,
PhD
Tue, Sep 4 at 11:20-12:20 PM in Stuyvesant Room
Panel: Rational Immuno-oncology Combinations Are Not Necessarily
Predictive
- Presenter: Robert B. Stein, MD,
PhD
Tue, Sep 4 at 1:55-2:55 PM in Stuyvesant Room
Panel: Vaccine & Antibiotics Can't Be Developed For Some
Intractable Infectious Diseases
About Agenus Inc.
Agenus is a clinical-stage immuno-oncology company focused on
the discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, proprietary cancer vaccine platforms, and
adoptive cell therapies (through its AgenTus Therapeutics
subsidiary). The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus' upcoming
presentation. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Through AgenTus Therapeutics, a subsidiary of
Agenus
View original content with
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-annual-b-riley-fbr-healthcare-conference-in-new-york-city-300706221.html
SOURCE Agenus Inc.